Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Volume 31, Supplement—May 2025
SUPPLEMENT ISSUE
Supplement

16S Ribosomal RNA Gene PCR and Sequencing for Pediatric Infection Diagnosis, United States, 2020–2023

Guyu LiComments to Author , Christopher A. Reis, Rebecca M. Kruc, Ziyuan Zhang, Nicholas T. Streck, Elizabeth H. Ristagno, Jay Mandrekar, Matthew J. Wolf, James T. Gaensbauer, and Robin Patel
Author affiliation: Mayo Clinic, Rochester, Minnesota, USA (G. Li, C.A. Reis, R.M. Kruc, N.T. Streck, E.H. Ristagno, J. Mandrekar, M.J. Wolf, J.T. Gaensbauer, R. Patel); Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA (Z. Zhang)

Main Article

Table 1

Patient characteristics from study of 16S ribosomal RNA gene PCR and sequencing for pediatric infection diagnosis, Mayo Clinic, Rochester, Minnesota, USA, 2020–2023*

Patient characteristics Value, n = 124 patients
Median age, y (IQR)
9.6 (2.2–15.0)
Sex
F 58 (47)
M
66 (53)
Immunocompromised host†
24 (20)
Intensive care unit admission
46 (37)
Suspected clinical syndrome
Meningoencephalitis 38 (31)
Musculoskeletal infection: septic arthritis, osteomyelitis 33 (27)
Pleural effusion 10 (8)
Surgical wound infection, including hardware infection 10 (8)
Lymphadenopathy 5 (4)
Bone mass 4 (3)
Intracranial abscess/fluid collection 2 (2)
Pericardial effusion 4 (3)
Pulmonary nodules 4 (3)
Traumatic wound infection 4 (3)
Intraabdominal abscess/fluid collection 4 (3)
Endocarditis 2 (2)
Splenic mass 1 (1)
Infected pseudoaneurysms 1 (1)
Mediastinitis 1 (1)
Retinal detachment 1 (1)
Suggested by pediatric infectious diseases team 56 (45)

*Values are no. (%) patients except as indicated. IQR, interquartile range. †Immunocompromised hosts include those with history of solid organ transplant, history of hematopoietic stem cell transplant, active chemotherapy, or receiving an immunosuppressive agent.

Main Article

Page created: April 11, 2025
Page updated: May 08, 2025
Page reviewed: May 08, 2025
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external